

- American Cancer Society. *Cancer Facts and Figures 2014*. Atlanta, GA: American Cancer Society; 2014.
- Shepherd J, Sideri M, Benedet J, et al. Carcinoma of the vagina. *J Epidemiol Biostat* 1998;3:103–109.
- Eddy CL, Marks RD, Miller MC, et al. Primary invasive vaginal carcinoma. *Am J Obstet Gynecol* 1991;165:292–296.
- Frank SJ, Jhingran A, Levenback C, et al. Definitive radiation therapy for squamous cell carcinoma of the vagina. *Int J Radiat Oncol Biol Phys* 2005;62:138–147.
- Hoffman MS, De Cesare LS, Roberts WS, et al. Upper vaginectomy for in situ and occult, superficially invasive carcinoma of the vagina. *Am J Obstet Gynecol* 1992;166:30–33.
- Kalogirou D, Antoniou G, Karakitsos P, et al. Vaginal intraepithelial neoplasia (VAIN) following hysterectomy in patients treated for carcinoma in situ of the cervix. *Eur J Gynaecol Oncol* 1997;18:188–191.
- International Agency for Research on Cancer (IARC). *Monographs on the Evaluation of Carcinogenic Risks to Humans. Human Papillomaviruses*. Vol 64. Lyon, France: IARC; 1995.
- Castle PE, Schiffman M, Bratti MC, et al. A population-based study of vaginal human papillomavirus infection in hysterectomized women. *J Infect Dis* 2004;190:458–467.
- Schraub S, Sun XS, Maingon P, et al. Cervical and vaginal cancer associated with pessary use. *Cancer* 1992;69:2505–2509.
- Pride GL, Schultz AE, Chuprevich TW, et al. Primary invasive squamous carcinoma of the vagina. *Obstet Gynecol* 1979;53:218–225.
- Beller U, Benedet J, Creasman W, et al. Carcinoma of the vagina. *Int J Gynaecol Obstet* 2006;95:S29–S42.
- Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina. Association of maternal stilboestrol therapy with tumor appearing in young women. *N Engl J Med* 1971;284:878–881.
- Palmer JR, Anderson D, Helmrich SP, et al. Risk factors for diethylstilbestrol-associated clear cell adenocarcinoma. *Obstet Gynecol* 2000;95:814–820.
- Waggoner SE, Anderson SM, Van Eyck S, et al. Human papillomavirus detection and p53 expression in clear-cell adenocarcinoma of the vagina and cervix. *Obstet Gynecol* 1994;84:404–408.
- Senekjian E, Frey K, Anderson D, et al. Local therapy in stage I clear cell adenocarcinoma of the vagina. *Cancer* 1987;60:1319–1324.
- Scully RE, Welch WR. Pathology of the female genital tract after prenatal exposure to diethylstilbestrol. In: Herbst AL, Bern HA, eds. *Developmental Effects of Diethylstilbestrol (DES) in Pregnancy*. New York, NY: Thieme-Stratton; 1981:26.
- Hatch EE, Palmer JR, Titus-Ernstoff L, et al. Cancer risk in women exposed to diethylstilbestrol in utero. *JAMA* 1998;280:630–634.
- Palmer JR, Wise LA, Hatch EE, et al. Prenatal diethylstilbestrol exposure and risk of breast cancer. *Cancer Epidemiol Biomarkers Prev* 2006;15:1509–1514.
- Hoover RN, Hyer M, Pfeiffer RM, et al. Adverse health outcomes in women exposed in utero to diethylstilbestrol. *N Engl J Med* 2011;365:1304–1314.
- Kirkbride P, Fyles A, Rawlings GA, et al. Carcinoma of the vagina—experience at the Princess Margaret Hospital (1974–1989). *Gynecol Oncol* 1995;56:435–443.
- Perez CA, Grigsby PW, Garipagaoglu M, et al. Factors affecting long-term outcome of irradiation in carcinoma of the vagina. *Int J Radiat Oncol Biol Phys* 1999;44:37–45.
- Plentl AA, Friedman EA. Lymphatics of the vagina. In: Plentl AA, Friedman EA, eds. *Lymphatic System of Female Genitalia*. Philadelphia, PA: W. B. Saunders, 1971:51.
- Davis KP, Stanhope CR, Garton GR, et al. Invasive vaginal carcinoma: analysis of early-stage disease. *Gynecol Oncol* 1991;42:131–136.
- Creasman WT, Phillips JL, Menck HR. The National Cancer Data Base report on cancer of the vagina. *Cancer* 1998;83:1033–1040.
- Frank SJ, Deavers MT, Jhingran A, et al. Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. *Gynecol Oncol* 2007;105:470–474.
- Coleman NM, Smith-Zagone MJ, Tanyi J, et al. Primary neuroendocrine carcinoma of the vagina with Merkel cell carcinoma phenotype. *Am J Surg Pathol* 2006;30:405–410.
- Buchanan DJ, Schlaerth J, Kurosaki T. Primary vaginal melanoma: thirteen-year disease-free survival after wide local excision and review of recent literature. *Am J Obstet Gynecol* 1998;178:1177–1184.
- Peters WA 3rd, Kumar NB, Andersen WA, et al. Primary sarcoma of the adult vagina: a clinicopathologic study. *Obstet Gynecol* 1985;65:699–704.
- Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): major lessons from the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. *Sarcoma* 2001;5:9–15.
- Kucera H, Vavra N. Radiation management of primary carcinoma of the vagina: clinical and histopathological variables associated with survival. *Gynecol Oncol* 1991;40:12–16.
- American Joint Committee on Cancer. Vagina. In: Edge SB, Byrd DR, Compton CC, et al., eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2010:387.
- Stock RG, Chen AS, Seski J. A 30-year experience in the management of primary carcinoma of the vagina: analysis of prognostic factors and treatment modalities. *Gynecol Oncol* 1995;56:45–52.
- Kucera H, Mock U, Knocke TH, et al. Radiotherapy alone for invasive vaginal cancer: outcome with intracavitary high dose rate brachytherapy versus conventional low dose rate brachytherapy. *Acta Obstet Gynecol Scand* 2001;80:355–360.
- Chyle V, Zagars GK, Wheeler JA, et al. Definitive radiotherapy for carcinoma of the vagina: outcome and prognostic factors. *Int J Radiat Oncol Biol Phys* 1996;35:891–905.
- Benedet JL, Saunders BH. Carcinoma in situ of the vagina. *Am J Obstet Gynecol* 1984;148:695–700.
- Cheng D, Ng TY, Ngan HY, et al. Wide local excision (WLE) for vaginal intraepithelial neoplasia (VAIN). *Acta Obstet Gynecol Scand* 1999;78:648–652.
- MacLeod C, Fowler A, Dalrymple C, et al. High-dose-rate brachytherapy in the management of high-grade intraepithelial neoplasia of the vagina. *Gynecol Oncol* 1997;65:74–77.
- Ogino I, Kitamura T, Okajima H, et al. High-dose-rate intracavitary brachytherapy in the management of cervical and vaginal intraepithelial neoplasia [see comments]. *Int J Radiat Oncol Biol Phys* 1998;40:881–887.
- Spiritos N, Doshi B, Kapp D, et al. Radiation therapy for primary squamous cell carcinoma of the vagina: Stanford University experience. *Gynecol Oncol* 1989;35:20–26.
- Benson C, Soisson AP, Carlson J, et al. Neovaginal reconstruction with a rectus abdominis myocutaneous flap. *Obstet Gynecol* 1993;81:871–875.
- Lee WR, Marcus RB, Sombeck MD, et al. Radiotherapy alone for carcinoma of the vagina: the importance of overall treatment time. *Int J Radiat Oncol Biol Phys* 1994;29:983–988.
- Thigpen T, Blessing J, Homesley HD, et al. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group study. *Gynecol Oncol* 1986;23:101–104.
- Eifel PJ. Concurrent chemotherapy and radiation: a major advance for women with cervical cancer. *J Clin Oncol* 1999;17:1334–1335.
- Dalrymple JL, Russell AH, Lee SW, et al. Chemoradiation for primary invasive squamous carcinoma of the vagina. *Int J Gynecol Cancer* 2004;14:110–117.
- Miyamoto DT, Viswanathan AN. Concurrent chemoradiation for vaginal cancer. *PLoS One* 2013;8:e65048.
- Beller U, Quinn M, Benedet J, et al. Carcinoma of the vulva. *Int J Gynaecol Obstet* 2006;95:S7–S26.
- Shepherd J, Sideri M, Benedet J, et al. Carcinoma of the vulva. *J Epidemiol Biostat* 1998;3:111–127.
- Hampel M, Deckers-Figiel S, Hampel JA, et al. New aspects of vulvar cancer: changes in localization and age of onset. *Gynecol Oncol* 2008;109:340–345.
- Crum CP, McLachlin CM, Tate JE, et al. Pathobiology of vulvar squamous neoplasia. *Curr Opin Obstet Gynecol* 1997;9:63–69.
- Hampel M, Sarajuuri H, Wentzensen N, et al. Effect of human papillomavirus vaccines on vulvar, vaginal, and anal intraepithelial lesions and vulvar cancer. *Obstet Gynecol* 2006;108:1361–1368.
- Trimble CL, Hildesheim A, Brinton LA, et al. Heterogeneous etiology of squamous carcinoma of the vulva. *Obstet Gynecol* 1996;87:59–64.
- Crum CP. Carcinoma of the vulva: epidemiology and pathogenesis. *Obstet Gynecol* 1992;79:448–454.
- Monk BJ, Burger RA, Lin F, et al. Prognostic significance of human papillomavirus (HPV) DNA in primary invasive vulvar cancer. *Obstet Gynecol* 1995;85:709–715.
- Haefner HK, Tate JE, McLachlin CM, et al. Vulvar intraepithelial neoplasia: age, morphological phenotype, papillomavirus DNA, and coexisting invasive carcinoma. *Hum Pathol* 1995;26:147–154.
- Lee YY, Wilczanski SP, Chumakov A, et al. Carcinoma of the vulva: HPV and p53 mutations. *Oncogene* 1994;9:1655–1659.
- Sliutz G, Schmidt W, Tempfer C, et al. Detection of p53 point mutations in primary human vulvar cancer by PCR and temperature gradient gel electrophoresis. *Gynecol Oncol* 1997;64:93–98.
- Andreasson B, Nyboe J. Predictive factors with reference to low-risk of metastases in squamous cell carcinoma in the vulvar region. *Gynecol Oncol* 1985;21:196–206.
- Binder SW, Huang I, Fu YS, et al. Risk factors for the development of lymph node metastasis in vulvar squamous carcinoma. *Gynecol Oncol* 1990;37:9–16.
- Hacker NF, Berek JS, Lagasse LD, et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. *Obstet Gynecol* 1983;61:408–412.
- Hoffman JS, Kumar NB, Morley GW. Microinvasive squamous carcinoma of the vulva: search for a definition. *Obstet Gynecol* 1983;61:615–618.
- Ross MJ, Ehrmann RL. Histologic prognosticators in stage I squamous cell carcinoma of the vulva. *Obstet Gynecol* 1987;70:774–784.
- Levenback C, Coleman RL, Burke TW, et al. Intraoperative lymphatic mapping and sentinel node identification with blue dye in patients with vulvar cancer. *Gynecol Oncol* 2001;83:276–281.
- Ridley CM, Frankman O, Jones IS, et al. New nomenclature for vulvar disease: report of the Committee on Terminology of the International Society for the Study of Vulvar Disease. *J Reprod Med* 1990;35:483–484.

64. Buscema J, Woodruff JD. Progressive histobiologic alterations in the development of vulvar cancer. *Am J Obstet Gynecol* 1980;138:146–150.
65. Brainard JA, Hart WR. Proliferative epidermal lesions associated with anogenital Paget's disease. *Am J Surg Pathol* 2000;24:543–552.
66. Koss LG, Brockunier AJ. Ultrastructural aspects of Paget's disease of the vulva. *Arch Pathol* 1969;87:592–600.
67. Fanning J, Lambert HC, Hale TM, et al. Paget's disease of the vulva: prevalence of associated vulvar adenocarcinoma, invasive Paget's disease, and recurrence after surgical excision. *Am J Obstet Gynecol* 1999;180:24–27.
68. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009;105:103–104.
69. Gil-Moreno A, Garcia-Jimenez A, Gonzalez-Bosquet J, et al. Merkel cell carcinoma of the vulva. *Gynecol Oncol* 1997;64:526–532.
70. Irvin WP, Cathro HP, Grosh WW, et al. Primary breast carcinoma of the vulva: a case report and literature review. *Gynecol Oncol* 1999;73:155–159.
71. Feakins RM, Lowe DC. Basal cell carcinoma of the vulva: a clinicopathologic study of 45 cases. *Int J Gynecol Pathol* 1997;16:319–324.
72. Japese H, van Dinh T, Woodruff JD. Verrucous carcinoma of the vulva: study of 24 cases. *Obstet Gynecol* 1982;60:462–466.
73. Carlson JW, McClennen RC, Gomez R, et al. Sebaceous carcinoma of the vulva: a case report and review of the literature. *Gynecol Oncol* 1996;60:489–491.
74. Weinstock MA. Malignant melanoma of the vulva and vagina in the United States: patterns of incidence and population-based estimates of survival. *Am J Obstet Gynecol* 1994;171:1225–1230.
75. Ragnarsson-Olding BK, Kanter-Levensohn LR, Lagerlof B, et al. Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. *Cancer* 1999;86:1273–1284.
76. Verschraegen CF, Benajipal M, Supakarpongkul W, et al. Vulvar melanoma at the M. D. Anderson Cancer Center: 25 years later. *Int J Gynecol Cancer* 2001;11:359–364.
77. Tasserou EW, van der Esch EP, Hart AA, et al. A clinicopathological study of 30 melanomas of the vulva. *Gynecol Oncol* 1992;46:170–175.
78. Curtin JP, Saigo P, Slucher B, et al. Soft-tissue sarcoma of the vagina and vulva: a clinicopathologic study. *Obstet Gynecol* 1995;86:269–272.
79. Nirenberg A, Østør AG, Slavin J, et al. Primary vulvar sarcomas. *Int J Gynecol Pathol* 1995;14:55–62.
80. Koppers V, Stiller M, Somville T, et al. Risk factors for recurrent VIN. Role of multifocality and grade of disease. *J Reprod Med* 1997;42:140–144.
81. Cohn DE, Dehdashti F, Gibb RK, et al. Prospective evaluation of positron emission tomography for the detection of groin node metastases from vulvar cancer. *Gynecol Oncol* 2002;85:179–184.
82. Homesley HD, Bundy BN, Sedlis A, et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). *Gynecol Oncol* 1993;49:279–283.
83. International Federation of Gynecology and Obstetrics. Staging announcement. FIGO staging of gynecologic cancers; cervical and vulva. *Int J Gynecol Cancer* 1995;5:319.
84. Hacker NF. Revised FIGO staging for carcinoma of the vulva. *Int J Gynaecol Obstet* 2009;105:105–106.
85. Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). *Am J Obstet Gynecol* 1991;164:997–1003, discussion 1003–1004.
86. Fons G, Hyde SE, Buist MR, et al. Prognostic value of bilateral positive nodes in squamous cell cancer of the vulva. *Int J Gynecol Cancer* 2009;19:1276–1280.
87. Origoni M, Sideri M, Garsia S, et al. Prognostic value of pathological patterns of lymph node positivity in squamous cell carcinoma of the vulva stage III and IVA FIGO. *Gynecol Oncol* 1992;45:313–316.
88. Landrum LM, Lanneau GS, Skaggs VJ, et al. Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era. *Gynecol Oncol* 2007;106:521–525.
89. Raspagliesi F, Hanozet F, Ditto A, et al. Clinical and pathological prognostic factors in squamous cell carcinoma of the vulva. *Gynecol Oncol* 2006;102:333–337.
90. Katz A, Eifel PJ, Jhingran A, et al. The role of radiation therapy in preventing regional recurrences of invasive squamous cell carcinoma of the vulva. *Int J Radiat Oncol Biol Phys* 2003;57:409–418.
91. Homesley HD, Bundy BN, Sedlis A, et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. *Obstet Gynecol* 1986;68:733–740.
92. Heaps JM, Fu YS, Montz FJ, et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. *Gynecol Oncol* 1990;38:309–314.
93. Pinto AP, Signorello LB, Crum CP, et al. Squamous cell carcinoma of the vulva in Brazil: prognostic importance of host and viral variables. *Gynecol Oncol* 1999;74:61–67.
94. Mariani L, Conti L, Atlante G, et al. Vulvar squamous carcinoma: prognostic role of DNA content. *Gynecol Oncol* 1998;71:159–164.
95. Smyczek-Gargya B, Volz B, Ceppert M, et al. A multivariate analysis of clinical and morphological prognostic factors in squamous cell carcinoma of the vulva. *Gynecol Obstet Invest* 1997;43:261–267.
96. Ansink AC, Krul MR, De Weger RA, et al. Human papillomavirus, lichen sclerosus, and squamous cell carcinoma of the vulva: detection and prognostic significance. *Gynecol Oncol* 1994;52:180–184.
97. Faul C, Miramow D, Gerszten K, et al. Isolated local recurrence in carcinoma of the vulva: prognosis and implications for treatment. *Int J Gynecol Cancer* 1998;8:409–414.
98. Berek JS, Hacker NF. *Practical Gynecologic Oncology*. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
99. Kenter CG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. *N Engl J Med* 2009;361:1838–1847.
100. Perez CA, Grigsby PW, Chao C, et al. Irradiation in carcinoma of the vulva: factors affecting outcome. *Int J Radiat Oncol Biol Phys* 1998;42:335–344.
101. Faul CM, Mirmow D, Huang Q, et al. Adjuvant radiation for vulvar carcinoma: improved local control. *Int J Radiat Oncol Biol Phys* 1997;38:381–389.
102. Grimshaw RN, Ghazal Aswad S, Monaghan JM. The role of ano-vulvectomy in locally advanced carcinoma of the vulva. *Int J Gynecol Cancer* 1991;1:15–18.
103. Hoffman MS, Cavanagh D, Roberts WS, et al. Ultra-radical surgery for advanced carcinoma of the vulva: an update. *Int J Gynecol Cancer* 1993;3:369–372.
104. Boronov RC. Combined therapy as an alternative to exenteration for locally advanced vulvo-vaginal cancer: rationale and results. *Cancer* 1982;49:1085–1091.
105. Fairey RN, MacKay PA, Benedet JL, et al. Radiation treatment of carcinoma of the vulva, 1950–1980. *Am J Obstet Gynecol* 1985;151:591–597.
106. Hacker NF, Berek JS, Juillard GJ, et al. Preoperative radiation therapy for locally advanced vulvar cancer. *Cancer* 1984;54:2056–2061.
107. Kunos C, Simpkins F, Gibbons H, et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. *Obstet Gynecol* 2009;114:537–546.
108. Leiserowitz GS, Russell AH, Kinney WK, et al. Prophylactic chemoradiation of inguino-femoral lymph nodes in patients with locally extensive vulvar cancer. *Gynecol Oncol* 1997;66:509–514.
109. Peterit DG, Mehta MP, Buchler DA, et al. A retrospective review of nodal treatment for vulvar cancer. *Am J Clin Oncol* 1993;16:38–42.
110. Stehman FB, Bundy BN, Thomas G, et al. Groin dissection versus groin radiation in carcinoma of the vulva: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 1992;24:389–396.
111. Koh WJ, Chiu M, Stelzer KJ, et al. Femoral vessel depth and the implications for groin node radiation. *Int J Radiat Oncol Biol Phys* 1993;27:969–974.
112. Stehman FB, Bundy BN, Dvoretzky PM, et al. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. *Obstet Gynecol* 1992;79:490–497.
113. Levenback C, Morris M, Burke TW, et al. Groin dissection practices among gynecologic oncologists treating early vulvar cancer. *Gynecol Oncol* 1996;62:73–77.
114. Micheletti L, Preti M, Zola P, et al. A proposed glossary of terminology related to the surgical treatment of vulvar carcinoma. *Cancer* 1998;83:1369–1375.
115. Levenback CF, van der Zee AG, Rob L, et al. Sentinel lymph node biopsy in patients with gynecologic cancers Expert panel statement from the International Sentinel Node Society Meeting, February 21, 2008. *Gynecol Oncol* 2009;114:151–156.
116. Van der Zee AG, Oonk MH, De Hullu JA, et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. *J Clin Oncol* 2008;26:884–889.
117. Oonk MH, van Hemel BM, Hollema H, et al. Size of sentinel-node metastasis and chances of non-sentinel-node involvement and survival in early stage vulvar cancer: results from GROINSS-V, a multicentre observational study. *Lancet Oncol* 2010;11:646–652.
118. Robison K, Roque D, McCourt C, et al. Long-term follow-up of vulvar cancer patients evaluated with sentinel lymph node biopsy alone. *Gynecol Oncol* 2014;133:416–420.
119. Levenback CF, Ali S, Coleman RL, et al. Lymphatic mapping and sentinel lymph node biopsy in women with squamous cell carcinoma of the vulva: a gynecologic oncology group study. *J Clin Oncol* 2012;30:3786–3791.
120. Berawal S, Coon D, Heron DE, et al. Preoperative intensity-modulated radiotherapy and chemotherapy for locally advanced vulvar carcinoma. *Gynecol Oncol* 2008;109:291–295.
121. Koh WJ, Wallace HJ, Greer BE, et al. Combined radiotherapy and chemotherapy in the management of local-regionally advanced vulvar cancer. *Int J Radiat Oncol Biol Phys* 1993;26:809–816.
122. Landoni F, Maneo A, Zanetta G, et al. Concurrent preoperative chemotherapy with 5-fluorouracil and mitomycin C and radiotherapy (FUMIR) followed by limited surgery in locally advanced and recurrent vulvar carcinoma. *Gynecol Oncol* 1996;61:321–327.
123. Landrum LM, Skaggs V, Gould N, et al. Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation. *Gynecol Oncol* 2008;108:584–590.
124. Lupi C, Raspagliesi F, Zucali R, et al. Combined preoperative chemoradiotherapy followed by radical surgery in locally advanced vulvar carcinoma: a pilot study. *Cancer* 1996;77:1472–1478.
125. Moore DH, Thomas GM, Montana GS, et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. *Int J Radiat Oncol Biol Phys* 1998;42:79–85.

126. Russell AH, Mesic JB, Scudder SA, et al. Synchronous radiation and cytotoxic chemotherapy for locally advanced or recurrent squamous cancer of the vulva. *Gynecol Oncol* 1992;47:14–20.
127. Scheistroen M, Tropé C. Combined bleomycin and irradiation in preoperative treatment of advanced squamous cell carcinoma of the vulva. *Acta Oncol* 1992;32:657–661.
128. Thomas G, Dembo A, DePetrillo A, et al. Concurrent radiation and chemotherapy in vulvar carcinoma. *Gynecol Oncol* 1989;34:263–267.
129. Eifel PJ, Winter K, Morris M, et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of Radiation Therapy Oncology Group trial (RTOG) 90-01. *J Clin Oncol* 2004;22:872–880.
130. Rose PG, Bundy BN, Watkins J, et al. Concurrent cisplatin-based chemotherapy and radiotherapy for locally advanced cervical cancer. *N Engl J Med* 1999;340:1144–1153.
131. Cummings B. Anal canal carcinomas. In Meyer JL, Vaeth JM, eds. *Frontiers in Radiation Oncology*. Vol 26. Basel, Switzerland: Karger; 1992:131.
132. Moore DH, Ali S, Koh WJ, et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncologic group study. *Gynecol Oncol* 2012;124:529–533.
133. Benedetti-Panici P, Greggi S, Scambia G, et al. Cisplatin, bleomycin, and methotrexate preoperative chemotherapy in locally advanced vulvar carcinoma. *Gynecol Oncol* 1993;50:49–53.
134. Domingues AP, Mota F, Durao M, et al. Neoadjuvant chemotherapy in advanced vulvar cancer. *Int J Gynecol Cancer* 2010;20:294–298.
135. Farias-Eisner R, Cirsiano FD, Grouse D, et al. Conservative and individualized surgery for early squamous cell carcinoma of the vulva: the treatment of choice for stage I and II (T1-2 N0-1 M0) disease. *Gynecol Oncol* 1994;53:55–58.
136. Hacker NF, Berek JS, Lagasse LD, et al. Individualization of treatment for stage I squamous cell vulvar carcinoma. *Obstet Gynecol* 1984;63:155–162.
137. Grimshaw RN, Murdoch JB, Monaghan JM. Radical vulvectomy and bilateral inguinal–emoral lymphadenectomy through separate incisions—experience with 100 cases. *Int J Gynecol Cancer* 1993;3:18–23.
138. Magrina JF, Gonzalez-Bosquet J, Weaver AL, et al. Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery. *Gynecol Oncol* 1998;71:116–121.
139. Magrina JF, Goodrich MA, Weaver AL, et al. Modified radical hysterectomy: morbidity and mortality. *Gynecol Oncol* 1995;59:277–282.
140. Burke TW, Levenback C, Coleman RL, et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. *Gynecol Oncol* 1995;57:215–220.
141. Horowitz NS, Olawaye AB, Borger DR, et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. *Gynecol Oncol* 2012;127:141–146.
142. International Agency for Research on Cancer. *GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012*. <http://globocan.iarc.fr>.
143. Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. *CA Cancer J Clin* 1995;45:8–30.
144. Bosch FX, de Sanjose S. Chapter 1: Human papillomavirus and cervical cancer—burden and assessment of causality. *J Natl Cancer Inst Monogr* 2003;31:3–13.
145. American Cancer Society. *Cancer Facts and Figures 2009*. Atlanta, GA: American Cancer Society; 2009.
146. Coughlin SS, Uhler RJ, Richards T, et al. Breast and cervical cancer screening practices among Hispanic and non-Hispanic women residing near the United States-Mexico border, 1999–2000. *Fam Community Health* 2003;26:130–139.
147. Castellsagué X, Diaz M, Vaccarella S, et al. Intrauterine device use, cervical infection with human papillomavirus, and risk of cervical cancer: a pooled analysis of 26 epidemiological studies. *Lancet Oncol* 2011;12:1023–1031.
148. Castellsagué X, Bosch FX, Muñoz N, et al. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. *N Engl J Med* 2002;346:1105–1112.
149. Smith HO, Tiffany MF, Qualls CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. *Gynecol Oncol* 2000;78:97–105.
150. Thomas DB, Ray RM. Oral contraceptives and invasive adenocarcinomas and adenocarcinomas of the uterine cervix: the World Health Organization Collaborative Study of Neoplasia and Steroid Contraceptives. *Am J Epidemiol* 1996;144:281–289.
151. Stubblefield PG. Oral contraceptives and neoplasia. *J Reprod Med* 1984;29:524–529.
152. Buehler JW, Ward JW. A new definition for AIDS surveillance. *Ann Intern Med* 1993;118:390–392.
153. Chirenje ZM. HIV and cancer of the cervix. *Best Pract Res Clin Obstet Gynaecol* 2005;19:269–276.
154. De Vuyst H, Lillo F, Broutet N, et al. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. *Eur J Cancer Prev* 2008;17:545–554.
155. Fairley CK, Chen S, Tabrizi SN, et al. Prevalence of HPV DNA in cervical specimens in women with renal transplants: a comparison with dialysis-dependent patients and patients with renal impairment. *Nephrol Dial Transplant* 1994;9:416–420.
156. Serur E, Fruchter RG, Maiman M, et al. Age, substance abuse, and survival of patients with cervical carcinoma. *Cancer* 1995;75:2530–2538.
157. Dunne EF, Unger ER, Sternberg M, et al. Prevalence of HPV infection among females in the United States. *JAMA* 2007;297:813–819.
158. Roden R, Wu TC. How will HPV vaccines affect cervical cancer? *Nat Rev Cancer* 2006;6:753–763.
159. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. *Lancet* 2006;367:1247–1255.
160. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. *N Engl J Med* 2007;356:1928–1943.
161. The Future II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. *N Engl J Med* 2007;356:1915–1927.
162. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. *Lancet* 2009;374:301–314.
163. Herrero R, Hildesheim A, Rodriguez AC, et al. Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica. *Vaccine* 2008;26:4795–4808.
164. Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. *JAMA* 2007;298:743–753.
165. Richart RM, Barron BA. A follow-up study of patients with cervical dysplasia. *Am J Obstet Gynecol* 1969;105:386–393.
166. Kivlahan C, Ingram E. Papanicolaou smears without endocervical cells. Are they inadequate? *Acta Cytol* 1986;30:258–260.
167. Plentl AA, Friedman EA. Lymphatics of the cervix uteri. In Plentl AA, Friedman EA, eds. *Lymphatic System of Female Genitalia*. Philadelphia, PA: W. B. Saunders; 1971:75.
168. Girardi F, Haas J. The importance of the histologic processing of pelvic lymph nodes in the treatment of cervical cancer. *Int J Gynecol Cancer* 1993;3:12–17.
169. Choi HJ, Ju W, Myung SK, et al. Diagnostic performance of computer tomography, magnetic resonance imaging, and positron emission tomography or positron emission tomography/computer tomography for detection of metastatic lymph nodes in patients with cervical cancer: meta-analysis. *Cancer Sci* 2010;101:1471–1479.
170. Fontanilla HP, Klopp AH, Lindberg ME, et al. Anatomic distribution of [(18) F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. *Pract Radiat Oncol* 2013;3:45–53.
171. Schneider V. Should the Bethesda System terminology be used in diagnostic surgical pathology?: Counterpoint. *Int J Gynecol Pathol* 2003;22:13–17.
172. Manos MM, Kinney WK, Hurlley LB, et al. Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results [see comments]. *JAMA* 1999;281:1605–1610.
173. Alli PM, Ali SZ. Atypical squamous cells of undetermined significance—rule out high-grade squamous intraepithelial lesion: cytopathologic characteristics and clinical correlates. *Diagn Cytopathol* 2003;28:308–312.
174. Schiffman M, Solomon D. Findings to date from the ASCUS-LSIL Triage Study (ALTS). *Arch Pathol Lab Med* 2003;127:946–949.
175. Cox JT, Schiffman M, Solomon D. Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. *Am J Obstet Gynecol* 2003;188:1406–1412.
176. Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda System: terminology for reporting results of cervical cytology. *JAMA* 2002;287:2114–2119.
177. Richart RM. Cervical intraepithelial neoplasia. In *Pathology Annual*. Vol 8. East Norwalk, CT: Appleton-Century-Crofts; 1973:301.
178. Azodi M, Chambers SK, Rutherford TJ, et al. Adenocarcinoma in situ of the cervix: management and outcome. *Gynecol Oncol* 1999;73:348–353.
179. Wolf JK, Levenback C, Malpica A, et al. Adenocarcinoma in situ of the cervix: significance of cone biopsy margins. *Obstet Gynecol* 1996;88:82–86.
180. Zaino RJ. Adenocarcinoma in situ, glandular dysplasia, and early invasive adenocarcinoma of the uterine cervix. *Int J Gynecol Pathol* 2002;21:314–326.
181. Kostopoulou E, Keating JT, Crum CP. Pathology. In: Eifel PJ, Levenback C, eds. *Cancer of the Female Lower Genital Tract*. London: B C Decker, Inc.; 2001:9.
182. Reich O, Pickel H, Tamussino K, et al. Microinvasive carcinoma of the cervix: site of first focus of invasion. *Obstet Gynecol* 2001;97:890–892.
183. Creasman WT, Zaino RJ, Major FJ, et al. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. *Am J Obstet Gynecol* 1998;178:62–65.
184. Robert ME, Fu YS. Squamous cell carcinoma of the uterine cervix: a review with emphasis on prognostic factors and unusual variants. *Semin Diagn Pathol* 1990;7:173–189.
185. Jennings RH, Barclay DL. Verrucous carcinoma of the cervix. *Cancer* 1972;30:430–434.
186. Brown J, Broadbudd R, Koeller M, et al. Sarcomatoid carcinoma of the cervix. *Gynecol Oncol* 2003;90:23–28.

187. Young RH, Clement PB. Endocervical adenocarcinoma and its variants: their morphology and differential diagnosis. *Histopathology* 2002;41:185–207.
188. Hirai Y, Takeshima N, Haga A, et al. A clinicocytopathologic study of adenoma malignum of the uterine cervix. *Gynecol Oncol* 1998;70:219–223.
189. Ferry JA, Scully RE. "Adenoid cystic" carcinoma and adenoid basal cell carcinoma of the uterine cervix: a study of 28 cases. *Am J Surg Pathol* 1988;12:134–144.
190. Zhou C, Gilks CB, Hayes M, et al. Papillary serous carcinoma of the uterine cervix: a clinicopathologic study of 17 cases. *Am J Surg Pathol* 1998;22:113–120.
191. Albores-Saavedra J, Gersell D, Gilks CB, et al. Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. *Arch Pathol Lab Med* 1997;121:34–39.
192. Wang Y, Mei K, Xiang MF, et al. Clinicopathological characteristics and outcome of patients with small cell neuroendocrine carcinoma of the uterine cervix: case series and literature review. *Eur J Gynaecol Oncol* 2013;34:307–310.
193. Chang TC, Lai CH, Tseng CJ, et al. Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy. *Cancer* 1998;83:712–718.
194. Hoskins PJ, Swenerton KD, Pike JA, et al. Small-cell carcinoma of the cervix: fourteen years of experience at a single institution using a combined-modality regimen of involved-field irradiation and platinum-based combination chemotherapy. *J Clin Oncol* 2003;21:3495–3501.
195. Viswanathan AN, Deavers MT, Jhingran A, et al. Small cell neuroendocrine carcinoma of the cervix: outcome and patterns of recurrence. *Gynecol Oncol* 2004;93:27–33.
196. Ross JC, Eifel PJ, Cox RS, et al. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. *Am J Surg Pathol* 1983;7:715–729.
197. ACOG Committee on Practice Bulletins—Gynecology. ACOG Practice Bulletin no. 109: Cervical cytology screening. *Obstet Gynecol* 2009;114:1409–1420.
198. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. *Am J Clin Pathol* 2012;137:516–542.
199. Moyer VA. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2012;156:880–891.
200. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. *Lancet Oncol* 2011;12:663–672.
201. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. *Lancet Oncol* 2012;13:78–88.
202. Keller MJ, Burk RD, Xie X, et al. Risk of cervical precancer and cancer among HIV-infected women with normal cervical cytology and no evidence of oncogenic HPV infection. *JAMA* 2012;308:362–369.
203. Arbyn M, Bergeron C, Klinkhamer P, et al. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. *Obstet Gynecol* 2008;111:167–177.
204. Cox JT. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management. *Obstet Gynecol Surv* 2006;61:S15–S25.
205. Reid R, Herschman BR, Crum CP, et al. Genital warts and cervical cancer. V. The tissue basis of colposcopic change. *Am J Obstet Gynecol* 1984;149:293–303.
206. Benedet JL, Anderson GH, Boyes DA. Colposcopic accuracy in the diagnosis of microinvasive and occult invasive carcinoma of the cervix. *Obstet Gynecol* 1985;65:557–562.
207. Kobak WH, Roman LD, Felix JC, et al. The role of endocervical curettage at cervical conization for high-grade dysplasia. *Obstet Gynecol* 1995;85:197–201.
208. Weitzman GA, Korhonen MO, Reeves KO, et al. Endocervical brush cytology. An alternative to endocervical curettage? *J Reprod Med* 1988;33:677–683.
209. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. *Ann Intern Med* 2000;132:810–819.
210. Bipat S, Glas AS, van der Velden J, et al. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: a systematic review. *Gynecol Oncol* 2003;91:59–66.
211. Heller PB, Barnhill DR, Mayer AR, et al. Cervical carcinoma found incidentally in a uterus removed for benign disease. *Obstet Gynecol* 1986;67:187–190.
212. Grigsby PW. PET/CT imaging to guide cervical cancer therapy. *Future Oncol* 2009;5:953–958.
213. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. *Int J Gynaecol Obstet* 2009;105:103–104.
214. Pecorelli S, Zigliani L, Odicino F. Revised FIGO staging for carcinoma of the cervix. *Int J Gynaecol Obstet* 2009;105:103–104.
215. Eifel PJ. Problems with the Clinical Staging of Carcinoma of the Cervix. *Semin Radiat Oncol* 1994;4:1–8.
216. American Joint Committee on Cancer. Cervix uteri. In: Edge SB, Byrd DR, Compton CC, et al., eds. *AJCC Cancer Staging Manual*. 7th ed. New York, NY: Springer; 2010:395.
217. Weiser EB, Bundy BN, Hoskins WJ, et al. Extraperitoneal versus transperitoneal selective paraaortic lymphadenectomy in the pretreatment surgical staging of advanced cervical carcinoma (a Gynecologic Oncology Group study). *Gynecol Oncol* 1989;33:283–289.
218. Schlaerth J, Spiritos N, Carson LF, et al. Laparoscopic retroperitoneal lymphadenectomy followed by immediate laparotomy in women with cervical cancer: a Gynecologic Oncology Group study. *Gynecol Oncol* 2002;85:81–88.
219. Lowe MP, Bahador A, Muderspach LI, et al. Feasibility of laparoscopic extraperitoneal surgical staging for locally advanced cervical carcinoma in a gynecologic oncology fellowship training program. *J Minim Invasive Gynecol* 2006;13:391–397.
220. Walker JL, Piedmonte MR, Spiritos NM, et al. Laparoscopy compared with laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group Study LAP2. *J Clin Oncol* 2009;27:5331–5336.
221. Euscher ED, Malpica A, Atkinson EN, et al. Ultrastaging improves detection of metastases in sentinel lymph nodes of uterine cervix squamous cell carcinoma. *Am J Surg Pathol* 2008;32:1336–1343.
222. Gortzak-Uzan L, Jimenez W, Nofech-Mozes S, et al. Sentinel lymph node biopsy vs. pelvic lymphadenectomy in early stage cervical cancer: is it time to change the gold standard? *Gynecol Oncol* 2010;116:28–32.
223. Lécuru F, Mathevet P, Querleu D, et al. Bilateral negative sentinel nodes accurately predict absence of lymph node metastasis in early cervical cancer: results of the SENTICOL study. *J Clin Oncol* 2011;29:1686–1691.
224. Frumovitz M, Querleu D, Gil-Moreno A, et al. Lymphadenectomy in locally advanced cervical cancer study (LiLACS): Phase III clinical trial comparing surgical with radiologic staging in patients with stages IB2-IVA cervical cancer. *J Minim Invasive Gynecol* 2014;21:3–8.
225. Cosin JA, Fowler JM, Chen MD, et al. Pretreatment surgical staging of patients with cervical carcinoma: the case for lymph node debulking. *Cancer* 1998;82:2241–2248.
226. Hacker NF, Wain GV, Nicklin JL. Resection of bulky positive lymph nodes in patients with cervical carcinoma. *Int J Gynecol Cancer* 1995;5:250–256.
227. Eifel PJ, Jhingran A, Levenback CF, et al. Predictive value of a proposed subclassification of stages I and II cervical cancer based on clinical tumor diameter. *Int J Gynecol Cancer* 2009;19:2–7.
228. Averette HE, Lichtinger M, Sevin BU, et al. Pelvic exenteration: a 150-year experience in a general hospital. *Am J Obstet Gynecol* 1970;150:179–184.
229. Delgado G, Bundy B, Zaino R, et al. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol* 1990;38:352–357.
230. Inoue T, Chihara T, Morita K. The prognostic significance of the size of the largest nodes in metastatic carcinoma from the uterine cervix. *Gynecol Oncol* 1984;19:187–193.
231. Kristensen GB, Abeler VM, Risberg B, et al. Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma. *Gynecol Oncol* 1999;74:245–251.
232. Boyce J, Fruchter R, Nicastrì A, et al. Prognostic factors in stage I carcinoma of the cervix. *Gynecol Oncol* 1981;12:154–165.
233. Delgado G, Bundy BN, Fowler WC, et al. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol* 1989;36:314–320.
234. Roman LD, Felix JC, Muderspach LI, et al. Influence of quantity of lymphovascular space invasion on the risk of nodal metastases in women with early-stage squamous cancer of the cervix [see comments]. *Gynecol Oncol* 1998;68:220–225.
235. Sevin BU, Lu Y, Bloch DA, et al. Surgically defined prognostic parameters in patients with early cervical carcinoma. A multivariate survival tree analysis. *Cancer* 1996;78:1438–1446.
236. Zreik TC, Chambers JT, Chambers SK. Parametrial involvement, regardless of nodal status: a poor prognostic factor for cervical cancer. *Obstet Gynecol* 1996;87:741–746.
237. Noguchi H, Shiozawa I, Kitahara T, et al. Uterine body invasion of carcinoma of the uterine cervix as seen from surgical specimens. *Gynecol Oncol* 1988;30:173–182.
238. Kainz C, Gitsch G, Tempfer C, et al. Vascular space invasion and inflammatory stromal reaction as prognostic factors in patients with surgically treated cervical cancer stage IB to IIB. *Anticancer Res* 1994;14:2245–2248.
239. Noh JM, Park W, Kim YS, et al. Comparison of clinical outcomes of adenocarcinoma and adenosquamous carcinoma in uterine cervical cancer patients receiving surgical resection followed by radiotherapy: a multicenter retrospective study (KROC 13-10). *Gynecol Oncol* 2014;132:618–623.
240. Berek JS, Hacker NS, Fu YS, et al. Adenocarcinoma of the uterine cervix: histologic variables associated with lymph node metastasis and survival. *Obstet Gynecol* 1985;65:46–52.
241. Eifel PJ, Burke TW, Delclos L, et al. Early stage I adenocarcinoma of the uterine cervix: treatment results in patients with tumors less than or equal to 4 cm in diameter. *Gynecol Oncol* 1991;41:199–205.

242. Eifel PJ, Burke TW, Morris M, et al. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. *Gynecol Oncol* 1995;59:38–44.
243. Eifel PJ, Morris M, Oswald MJ, et al. Adenocarcinoma of the uterine cervix. Prognosis and patterns of failure in 367 cases. *Cancer* 1990;65:2507–2514.
244. Gien LT, Beauchemin MC, Thomas G. Adenocarcinoma: a unique cervical cancer. *Gynecol Oncol* 2010;116:140–146.
245. Hopkins M, Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. *Obstet Gynecol* 1991;77:912–917.
246. Irie T, Kigawa J, Minagawa Y, et al. Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. *Eur J Surg Oncol* 2000;26:464–467.
247. Look KY, Brunetto VL, Clarke-Pearson DL, et al. An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecology Oncology Group study. *Gynecol Oncol* 1996;63:304–311.
248. Nakanishi T, Ishikawa H, Suzuki Y, et al. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. *Gynecol Oncol* 2000;79:289–293.
249. Shingleton HM, Bell MC, Fremgen A, et al. Is there really a difference in survival of women with squamous cell carcinoma, adenocarcinoma, and adenosquamous cell carcinoma of the cervix? *Cancer* 1995;76:1948–1955.
250. Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. *Gynecol Oncol* 2012;125:287–291.
251. Chan YM, Ng TY, Ngan HY, et al. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? *Gynecol Oncol* 2002;84:7–11.
252. Zanagnolo V, Minig LA, Gadducci A, et al. Surveillance procedures for patients for cervical carcinoma: a review of the literature. *Int J Gynecol Cancer* 2009;19:306–313.
253. Grogan M, Thomas GM, Melamed I, et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. *Cancer* 1999;86:1528–1536.
254. Bush R. The significance of anemia in clinical radiation therapy. *Int J Radiat Oncol Biol Phys* 1986;12:2047–2050.
255. Grigsby PW, Winter K, Wasserman TH, et al. Irradiation with or without misonidazole for patients with stages IIIB and IVA carcinoma of the cervix: final results of RTOG 80-05. Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1999;44:513–517.
256. Overgaard J, Bentzen SM, Kolstad P, et al. Misonidazole combined with radiotherapy in the treatment of carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1989;16:1069–1072.
257. Sundföer K, Trope C, Suo Z, et al. Normobaric oxygen treatment during radiotherapy for carcinoma of the uterine cervix: results from a prospective controlled randomized trial. *Radiother Oncol* 1999;50:157–165.
258. Maor MH, Gillespie BW, Peters LJ, et al. Neutron therapy in cervical cancer: results of a phase III RTOG study. *Int J Radiat Oncol Biol Phys* 1988;14:885–891.
259. Fyles A, Milosevic M, Hedley D, et al. Tumor hypoxia has independent predictor impact only in patients with node-negative cervix cancer. *J Clin Oncol* 2002;20:680–687.
260. Sundföer K, Lyng H, Rofstad EK. Tumour hypoxia and vascular density as predictors of metastasis in squamous cell carcinoma of the uterine cervix. *Br J Cancer* 1998;78:822–827.
261. Thomas G, Ali S, Hoebers FJ, et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. *Gynecol Oncol* 2008;108:317–325.
262. Klopp AH, Eifel PJ. Biological predictors of cervical cancer response to radiation therapy. *Semin Radiat Oncol* 2012;22:143–150.
263. Rutledge FN, Mitchell MR, Munsell M, et al. Youth as a prognostic factor in carcinoma of the cervix: a matched analysis. *Gynecol Oncol* 1992;44:123–130.
264. Estape R, Angioli R, Wagnan F, et al. Significance of intraperitoneal cytology in patients undergoing radical hysterectomy. *Gynecol Oncol* 1998;68:169–171.
265. Lopes A, Daras V, Cross PA, et al. Thrombocytosis as a prognostic factor in women with cervical cancer. *Cancer* 1994;74:90–92.
266. Gaffney DK, Holden J, Davis M, et al. Elevated cyclooxygenase-2 expression correlates with diminished survival in carcinoma of the cervix treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2001;49:1213–1217.
267. Tsai CJ, Sulman EP, Eifel PJ, et al. Galectin-7 levels predict radiation response in squamous cell carcinoma of the cervix. *Gynecol Oncol* 2013;131:645–649.
268. Gaffney DK, Haslam D, Tsodikov A, et al. Epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) negatively affect overall survival in carcinoma of the cervix treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;56:922–928.
269. Oka K, Suzuki Y, Iida H, et al. Pd-ECGF positivity correlates with better survival, while iNOS has no predictive value for cervical carcinomas treated with radiotherapy. *Int J Radiat Oncol Biol Phys* 2003;57:217–221.
270. Pilch H, Gunzel S, Schaffer U, et al. Human papillomavirus (HPV) DNA in primary cervical cancer and in cancer free pelvic lymph nodes—correlation with clinicopathological parameters and prognostic significance. *Zentralbl Gynakol* 2001;123:91–101.
271. Kobayashi Y, Yoshinouchi M, Tianqi G, et al. Presence of human papilloma virus DNA in pelvic lymph nodes can predict unexpected recurrence of cervical cancer in patients with histologically negative lymph nodes. *Clin Cancer Res* 1998;4:979–983.
272. McIntyre JB, Wu JS, Craighead PS, et al. (2013) PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. *Gynecol Oncol* 2012;128:409–414.
273. Kidd EA, El Naqa I, Siegel BA, et al. FDG-PET-based prognostic nomograms for locally advanced cervical cancer. *Gynecol Oncol* 2012;127:136–140.
274. Alvarez RD, Helm CW, Edwards R, et al. Prospective randomized trial of LLETZ versus laser ablation in patients with cervical intraepithelial neoplasia. *Gynecol Oncol* 1994;52:175–179.
275. Mitchell MF, Tortolero-Luna G, Cook E, et al. A randomized clinical trial of cryotherapy, laser vaporization, and loop electrosurgical excision for treatment of squamous intraepithelial lesions of the cervix. *Obstet Gynecol* 1998;92:737–744.
276. Kolstad P. Follow-up study of 232 patients with stage Ia1 and 411 patients with stage Ia2 squamous cell carcinoma of the cervix (microinvasive carcinoma). *Gynecol Oncol* 1989;33:265–272.
277. Diakomanolis E, Haidopoulos D, Rodolakis A, et al. Laser CO(2) conization: a safe mode of treating conservatively microinvasive carcinoma of the uterine cervix. *Eur J Obstet Gynecol Reprod Biol* 2004;113:229–233.
278. Morris M, Mitchell MF, Silva EG, et al. Cervical conization as definitive therapy for early invasive squamous carcinoma of the cervix. *Gynecol Oncol* 1993;51:193–207.
279. Phongnarisorn C, Srisomboon J, Khunamornpong S, et al. The risk of residual neoplasia in women with microinvasive squamous cervical carcinoma and positive cone margins. *Int J Gynecol Cancer* 2006;16:655–659.
280. Roman LD, Felix JC, Muderspach LI, et al. Risk of residual invasive disease in women with microinvasive squamous cancer in a conization specimen. *Obstet Gynecol* 1997;90:759–764.
281. Jakobsson M, Bruinsma F. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. *BMJ* 2008;337:a1350.
282. Ramirez PT, Pareja R, Rendon GJ, et al. Management of low-risk early-stage cervical cancer: should conization, simple trachelectomy, or simple hysterectomy replace radical surgery as the new standard of care? *Gynecol Oncol* 2014;132:254–259.
283. Xu L, Sun FQ, Wang ZH. Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review. *Acta Obstet Gynecol Scand* 2011;90:1200–1209.
284. Grigsby PW, Perez CA. Radiotherapy alone for medically inoperable carcinoma of the cervix: stage IA and carcinoma in situ. *Int J Radiat Oncol Biol Phys* 1991;21:375–378.
285. Hamberger AD, Fletcher GH, Wharton JT. Results of treatment of early stage I carcinoma of the uterine cervix with intracavitary radium alone. *Cancer* 1978;41:980–985.
286. Peters WA 3rd, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. *J Clin Oncol* 2000;18:1606–1613.
287. Rotman M, Sedlis A, Piedmonte MR, et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a gynecologic oncology group study. *Int J Radiat Oncol Biol Phys* 2006;65:169–176.
288. Burghardt E, Baltzer J, Tulusan AH, et al. Results of surgical treatment of 1028 cervical cancers studied with volumetry. *Cancer* 1992;70:648–655.
289. Alvarez RD, Potter ME, Soong SJ, et al. Rationale for using pathologic tumor dimensions and nodal status to subclassify surgically treated stage IB cervical cancer patients. *Gynecol Oncol* 1991;43:108–112.
290. Eifel PJ, Morris M, Wharton JT, et al. The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1994;29:9–16.
291. Perez CA, Grigsby PW, Nene SM, et al. Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone. *Cancer* 1992;69:2796–2806.
292. Landoni F, Maneo A, Colombo A, et al. Randomised study of radical surgery versus radiotherapy for stage Ib–IIa cervical cancer. *Lancet* 1997;350:535–540.
293. Alvarez RD, Gelder MS, Gore H, et al. Radical hysterectomy in the treatment of patients with bulky early stage carcinoma of the cervix uteri. *Surg Gynecol Obstet* 1993;176:539–542.
294. Bloss JD, Berman ML, Mukherjee J, et al. Bulky stage IB cervical carcinoma managed by primary radical hysterectomy followed by tailored radiotherapy. *Gynecol Oncol* 1992;47:21–27.
295. Rettenmaier MA, Casanova DM, Micha JP, et al. Radical hysterectomy and tailored postoperative radiation therapy in the management of bulky stage IB cervical cancer. *Cancer* 1989;63:2220–2223.
296. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy for bulky stage IB cervical carcinoma. *N Engl J Med* 1999;340:1154–1161.
297. Pellegrino A, Vizza E, Fruscio R, et al. Total laparoscopic radical hysterectomy and pelvic lymphadenectomy in patients with Ib1 stage cervical cancer: analysis of surgical and oncological outcome. *Eur J Surg Oncol* 2009;35:98–103.

298. Ramirez PT, Soliman PT, Schmeler KM, et al. Laparoscopic and robotic techniques for radical hysterectomy in patients with early-stage cervical cancer. *Gynecol Oncol* 2008;110:S21–S24.
299. Lowe MP, Chamberlain DH, Kamelle SA, et al. A multi-institutional experience with robotic-assisted radical hysterectomy for early stage cervical cancer. *Gynecol Oncol* 2009;113:191–194.
300. Orr JW, Shingleton HM. *Complications in Gynecologic Oncology: Prevention, Recognition and Management*. Philadelphia, PA: J B Lippincott; 1994.
301. Bergmark K, Avall-Lundqvist E, Dickman PW, et al. Lymphedema and bladder-emptying difficulties after radical hysterectomy for early cervical cancer and among population controls. *Int J Gynecol Cancer* 2006;16:1130–1139.
302. Hatch KD, Parham G, Shingleton H, et al. Ureteral strictures and fistulae following radical hysterectomy. *Gynecol Oncol* 1984;19:17–23.
303. Landoni F, Maneo A, Cormio G, et al. Class II versus class III radical hysterectomy in stage IB-IIA cervical cancer: a prospective randomized study. *Gynecol Oncol* 2001;80:3–12.
304. Uccella S, Laterza R, Ciravolo G, et al. A comparison of urinary complications following total laparoscopic radical hysterectomy and laparoscopic pelvic lymphadenectomy to open abdominal surgery. *Gynecol Oncol* 2007;107:S147–S149.
305. Pieterse QD, Maas CP, ter Kuile MM, et al. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. *Int J Gynecol Cancer* 2006;16:1119–1129.
306. Ralph G, Tamussino K, Lichtenegger W. Urological complications after radical hysterectomy with or without radiotherapy for cervical cancer. *Arch Gynecol Obstet* 1990;248:61–65.
307. Dargent D, Brun JL, Roy M, et al. Pregnancies following radical trachelectomy for invasive cervical cancer. *Gynecol Oncol* 1994;52:105 (abstract).
308. Covens A, Shaw P, Murphy J, et al. Is radical trachelectomy a safe alternative to radical hysterectomy for patients with stage IA-B carcinoma of the cervix? *Cancer* 1999;86:2273–2279.
309. Smith JR, Boyle DC, Corless DJ, et al. Abdominal radical trachelectomy: a new surgical technique for the conservative management of cervical carcinoma. *Br J Obstet Gynaecol* 1997;104:1196–1200.
310. Alexander-Sefre F, Chee N, Spencer C, et al. Surgical morbidity associated with radical trachelectomy and radical hysterectomy. *Gynecol Oncol* 2006;101:450–454.
311. Peppercorn PD, Jeyarajah AR, Woolas R, et al. Role of MR imaging in the selection of patients with early cervical carcinoma for fertility-preserving surgery: initial experience. *Radiology* 1999;212:395–399.
312. Jolley JA, Battista L, Wing DA. Management of pregnancy after radical trachelectomy: case reports and systematic review of the literature. *Am J Perinatol* 2007;24:531–539.
313. Thomas GM, Dembo AJ. Is there a role for adjuvant pelvic radiotherapy after radical hysterectomy in early stage cervical cancer? *Int J Gynecol Cancer* 1991;1:1.
314. Bandy LC, Clarke-Pearson DL, Soper JT, et al. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. *Gynecol Oncol* 1987;26:160–168.
315. Lowrey GC, Mendenhall WM, Million RR. Stage IB or IIA-B carcinoma of the intact uterine cervix treated with irradiation: a multivariate analysis. *Int J Radiat Oncol Biol Phys* 1992;24:205–210.
316. Mendenhall WM, McCarty PJ, Morgan LS, et al. Stage IB-IIA-B carcinoma of the intact uterine cervix greater than or equal to 6 cm in diameter: Is adjuvant extrafascial hysterectomy beneficial? *Int J Radiat Oncol Biol Phys* 1991;21:899–904.
317. Thoms WW Jr, Eifel PJ, Smith TL, et al. Bulky endocervical carcinoma: a 23-year experience. *Int J Radiat Oncol Biol Phys* 1992;23:491–499.
318. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the Gynecologic Oncology Group. *Gynecol Oncol* 2003;89:343–353.
319. Sardi JE, Giaroli A, Sananes C, et al. Long-term follow-up of the first randomized trial using neoadjuvant chemotherapy in stage Ib squamous carcinoma of the cervix: the final results. *Gynecol Oncol* 1997;67:61–69.
320. Eddy GL, Bundy BN, Creasman WT, et al. Treatment of (“bulky”) stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. *Gynecol Oncol* 2007;106:362–369.
321. Benedetti-Panici P, Greggi S, Colombo A, et al. Neoadjuvant chemotherapy and radical surgery versus exclusive radiotherapy in locally advanced squamous cell cervical cancer: results from the Italian multicenter randomized study. *J Clin Oncol* 2002;20:179–188.
322. Chang TC, Lai CH, Hong JH, et al. Randomized trial of neoadjuvant cisplatin, vincristine, bleomycin, and radical hysterectomy versus radiation therapy for bulky stage IB and IIA cervical cancer. *J Clin Oncol* 2000;18:1740–1747.
323. Barillot I, Horiot JC, Pigneux J, et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostic factors. *Int J Radiat Oncol Biol Phys* 1997;38:969–978.
324. Benedet J, Odicino F, Maisonneuve P, et al. Carcinoma of the cervix uteri. *J Epidemiol Biostat* 1998;3:5–34.
325. Logsdon MD, Eifel PJ. FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy. *Int J Radiat Oncol Biol Phys* 1999;43:763–775.
326. Fyles A, Keane TJ, Barton M, et al. The effect of treatment duration in the local control of cervix cancer. *Radiation Oncol* 1992;25:273–279.
327. Perez CA, Grigsby PW, Castro-Vita H, et al. Carcinoma of the uterine cervix. I. Impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy. *Int J Radiat Oncol Biol Phys* 1995;32:1275–1288.
328. Peterit DG, Sarkaria JN, Chappell R, et al. The adverse effect of treatment prolongation in cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1995;32:1301–1307.
329. Eifel PJ, Ho A, Khalid N, et al. Patterns of radiation therapy practice for patients treated for intact cervical cancer in 2005 to 2007: a quality research in radiation oncology study. *Int J Radiat Oncol Biol Phys* 2014;89:249–256.
330. Ahamad A, D'Souza W, Salehpour M, et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. *Int J Radiat Oncol Biol Phys* 2005;62:1117–1124.
331. Salama JK, Mundt AJ, Roeske J, et al. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. *Int J Radiat Oncol Biol Phys* 2006;65:1170–1176.
332. Small W Jr, Mell LK, Anderson P, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in post-operative treatment of endometrial and cervical cancer. *Int J Radiat Oncol Biol Phys* 2008;71:428–434.
333. Verma J, Sulman EP, Jhingran A, et al. Dosimetric predictors of duodenal toxicity after intensity modulated radiation therapy for treatment of the para-aortic nodes in gynecologic cancer. *Int J Radiat Oncol Biol Phys* 2014;88:357–362.
334. Beadle BM, Jhingran A, Salehpour M, et al. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. *Int J Radiat Oncol Biol Phys* 2009;73:235–241.
335. Haie C, Pejovic MH, Gerbaulet A, et al. Is prophylactic para-aortic irradiation worthwhile in the treatment of advanced cervical carcinoma? Results of a controlled clinical trial of the EORTC radiotherapy group. *Radiation Oncol* 1988;11:101–112.
336. Rotman M, Pajak M, Choi K, et al. Prophylactic extended-field irradiation of para-aortic lymph nodes in stages IIB and bulky IB and IIA cervical carcinomas. Ten-year treatment results of RTOG 79-20. *JAMA* 1995;274:387–393.
337. Rotman M, Aziz H, Eifel PJ. Irradiation of pelvic and paraaortic nodes in carcinoma of the cervix. *Semin Radiat Oncol* 1994;4:23.
338. Cunningham M, Dunton C, Corn B, et al. Extended-field radiation therapy in early-stage cervical carcinoma: survival and complications. *Gynecol Oncol* 1991;43:51–54.
339. Varia MA, Bundy BN, Deppe G, et al. Cervical carcinoma metastatic to para-aortic nodes: extended field radiation therapy with concomitant 5-fluorouracil and cisplatin chemotherapy: a Gynecologic Oncology Group study. *Int J Radiat Oncol Biol Phys* 1998;42:1015–1023.
340. Small W Jr, Winter K, Levenback C, et al. Extended-field irradiation and intracavitary brachytherapy combined with cisplatin chemotherapy for cervical cancer with positive para-aortic or high common iliac lymph nodes: results of ARM 1 of RTOG 0116. *Int J Radiat Oncol Biol Phys* 2007;68:1081–1087.
341. Erickson B, Eifel P, Moughan J, et al. Patterns of brachytherapy practice for patients with carcinoma of the cervix (1996–1999): a patterns of care study. *Int J Radiat Oncol Biol Phys* 2005;63:1083–1092.
342. Eifel PJ, Moughan J, Erickson B, et al. Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: a patterns of care study. *Int J Radiat Oncol Biol Phys* 2004;60:1144–1153.
343. Potish RA, Gerbi BJ, Engeler GP. Dose prescription, dose specification, and applicator geometry in intracavitary therapy. In Williamson JF, Thomadsen BR, Nath R, eds. *Brachytherapy Physics*. Madison, WI: Medical Physics Publishing; 1995: 379–410.
344. International Commission on Radiation Units and Measurements. *Dose and Volume Specification for Reporting Intracavitary Therapy in Gynecology*. Vol 38. Bethesda, MD: International Commission on Radiation Units and Measurements; 1985.
345. Pelloski CE, Palmer M, Chronowski GM, et al. Comparison between CT-based volumetric calculations and ICRU reference-point estimates of radiation doses delivered to bladder and rectum during intracavitary radiotherapy for cervical cancer. *Int J Radiat Oncol Biol Phys* 2005;62:131–137.
346. Potter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from gynaecological (GYN) GEC-ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiation Oncol* 2006;7:67–77.
347. Katz A, Eifel PJ. Quantification of intracavitary brachytherapy parameters and correlation with outcome in patients with carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 2000;48:1417–1425.
348. Viswanathan AN, Erickson BA. Three-dimensional imaging in gynecologic brachytherapy: a survey of the American Brachytherapy Society. *Int J Radiat Oncol Biol Phys* 2010;76:104–109.

349. Dimopoulos JC, Petrow P, Tanderup K, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (IV): Basic principles and parameters for MR imaging within the frame of image based adaptive cervix cancer brachytherapy. *Radiother Oncol* 2012;103:113–122.
350. Hellebust TP, Kirisits C, Berger D, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group: considerations and pitfalls in commissioning and applicator reconstruction in 3D image-based treatment planning of cervix cancer brachytherapy. *Radiother Oncol* 2010;96:153–160.
351. Pötter R, Haie-Meder C, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. *Radiother Oncol* 2006;78:67–77.
352. Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. *Radiother Oncol* 2005;74:235–245.
353. Georg P, Lang S, Dimopoulos JC, et al. Dose-volume histogram parameters and late side effects in magnetic resonance image-guided adaptive cervical cancer brachytherapy. *Int J Radiat Oncol Biol Phys* 2011;79:356–362.
354. Charra-Brunaud C, Harter V, Delannes M, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. *Radiother Oncol* 2012;103:305–313.
355. Haie-Meder C, Kramar A, Lambin P, et al. Analysis of complications in a prospective randomized trial comparing two brachytherapy low dose rates in cervical carcinoma. *Int J Radiat Oncol Biol Phys* 1994;29:953–960.
356. Amdur RJ, Bedford JS. Dose-rate effects between 0.3 and 30 Gy/h in a normal and a malignant human cell line [see comments]. *Int J Radiat Oncol Biol Phys* 1994;30:83–90.
357. Martinez A, Edmundson GK, Cox RS, et al. Combination of external beam irradiation and multiple-site perineal applicator (MUPIT) for treatment of locally advanced or recurrent prostatic, anorectal, and gynecologic malignancies. *Int J Radiat Oncol Biol Phys* 1985;11:391–398.
358. Syed AMN, Puthwala AA, Neblett D, et al. Transperineal interstitial-intracavitary “Syed-Neblett” applicator in the treatment of carcinoma of the uterine cervix. *Endocuriether Hyperther Oncol* 1986;2:1–13.
359. Hughes-Davies L, Silver B, Kapp D. Parametrial interstitial brachytherapy for advanced or recurrent pelvic malignancy: the Harvard/Stanford experience. *Gynecol Oncol* 1995;58:24–27.
360. Choi JC, Ingenito AC, Nanda RK, et al. Potential decreased morbidity of interstitial brachytherapy for gynecologic malignancies using laparoscopy: A pilot study. *Gynecol Oncol* 1999;73:210–215.
361. Erickson B, Gillin MT. Interstitial implantation of gynecologic malignancies. *J Surg Oncol* 1997;66:285–295.
362. Jhingran A, Eifel PJ. Perioperative and postoperative complications of intracavitary radiation for FIGO stage I–III carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 2000;46:1177–1183.
363. Eifel PJ, Levenback C, Wharton JT, et al. Time course and incidence of late complications in patients treated with radiation therapy for FIGO stage IB carcinoma of the uterine cervix. *Int J Radiat Oncol Biol Phys* 1995;32:1289–1300.
364. Perez CA, Grigsby PW, Lockett MA, et al. Radiation therapy morbidity in carcinoma of the uterine cervix: dosimetric and clinical correlation. *Int J Radiat Oncol Biol Phys* 1999;44:855–866.
365. Eifel PJ, Jhingran A, Bodurka DC, et al. Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. *J Clin Oncol* 2002;20:3651–3657.
366. Bruner DW, Lanciano R, Keegan M, et al. Vaginal stenosis and sexual function following intracavitary radiation for the treatment of cervical and endometrial carcinoma. *Int J Radiat Oncol Biol Phys* 1993;27:825–830.
367. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. *N Engl J Med* 1999;340:1137–1143.
368. Whitney CW, Sause W, Bundy BN, et al. A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB–IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. *J Clin Oncol* 1999;17:1339–1348.
369. Pearcey R, Brundage M, Drouin P, et al. A clinical trial comparing concurrent cisplatin and radiation therapy versus radiation alone for locally advanced squamous cell carcinoma of the cervix carried out by the National Cancer Institute of Canada Clinical Trials Group. *Proc Am Soc Clin Oncol* 2000;19:378a.
370. Eifel PJ. Chemoradiation for carcinoma of the cervix: advances and opportunities. *Radiat Res* 2000;154:229–236.
371. Pearcey R, Brundage M, Drouin P, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. *J Clin Oncol* 2002;20:966–972.
372. Thomas G, Dembo A, Ackerman I, et al. A randomized trial of standard versus partially hyperfractionated radiation with or without concurrent 5-fluorouracil in locally advanced cervical cancer. *Gynecol Oncol* 1998;69:137–145.
373. Lanciano R, Calkins A, Bundy BN, et al. Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study. *J Clin Oncol* 2005;23:8289–8295.
374. Wong LC, Ngan HY, Cheung AN, et al. Chemoradiation and adjuvant chemotherapy in cervical cancer. *J Clin Oncol* 1999;17:2055–2060.
375. Lorvidhaya V, Chitapanarux I, Sangruchi S, et al. Concurrent mitomycin C, 5-fluorouracil, and radiotherapy in the treatment of locally advanced carcinoma of the cervix: a randomized trial. *Int J Radiat Oncol Biol Phys* 2003;55:1226–1232.
376. Dueñas-González A, Zarbá JJ, Patel F, et al. Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. *J Clin Oncol* 2011;29:1678–1685.
377. Chen MD, Paley PJ, Potish RA, et al. Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. *Gynecol Oncol* 1997;67:131–136.
378. Muderspach LI, Curtin JP, Roman LD, et al. Carboplatin as a radiation sensitizer in locally advanced cervical cancer: a pilot study. *Gynecol Oncol* 1997;65:336–342.
379. Kang S, Nam BH, Park JY, et al. Risk assessment tool for distant recurrence after platinum-based concurrent chemoradiation in patients with locally advanced cervical cancer: a Korean gynecologic oncology group study. *J Clin Oncol* 2012;30:2369–2374.
380. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. *J Clin Oncol* 2008;26:5802–5812.
381. Pearcey R, Miao Q, Kong W, et al. Impact of adoption of chemoradiotherapy on the outcome of cervical cancer in Ontario: results of a population-based cohort study. *J Clin Oncol* 2007;25:2383–2388.
382. Chauvergne J, Rohart J, Héron JF, et al. [Randomized trial of initial chemotherapy in 151 locally advanced carcinoma of the cervix (T2b-N1, T3b, MO)]. *Bull Cancer* 1990;77:1007–1024.
383. Kumar L, Kaushal R, Nandy M, et al. Chemotherapy followed by radiotherapy versus radiotherapy alone in locally advanced cervical cancer: a randomized study. *Gynecol Oncol* 1994;54:307–315.
384. Leborgne F, Leborgne JH, Doldán R, et al. Induction chemotherapy and radiotherapy of advanced cancer of the cervix: a pilot study and phase III randomized trial. *Int J Radiat Oncol Biol Phys* 1997;37:343–350.
385. Sundfjör K, Trope CG, Hogberg T, et al. Radiotherapy and neoadjuvant chemotherapy for cervical carcinoma. A randomized multicenter study of sequential cisplatin and 5-fluorouracil and radiotherapy in advanced cervical carcinoma stage 3B and 4A. *Cancer* 1996;77:2371–2378.
386. Tattersall MH, Ramirez C, Coppleson M. A randomized trial comparing platinum-based chemotherapy followed by radiotherapy vs. radiotherapy alone in patients with locally advanced cervical cancer. *Int J Gynecol Cancer* 1992;2:244–251.
387. Souhami L, Gil R, Allan S, et al. A randomized trial of chemotherapy followed by pelvic radiation therapy in stage IIB carcinoma of the cervix. *Int J Radiat Oncol Biol Phys* 1991;9:970–977.
388. Thigpen JT, Blessing JA, DiSaia PJ, et al. A randomized comparison of a rapid versus prolonged (24 hr) infusion of cisplatin in therapy of squamous cell carcinoma of the uterine cervix: a Gynecologic Oncology Group study. *Gynecol Oncol* 1989;32:198–202.
389. Thigpen T, Shingleton H, Homesley H, et al. Cis-platinum in treatment of advanced or recurrent squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. *Cancer* 1981;48:899–903.
390. Cadron I, Van Gorp T, Amant F, et al. Chemotherapy for recurrent cervical cancer. *Gynecol Oncol* 2007;107:S113–S118.
391. Brader KR, Morris M, Levenback C, et al. Chemotherapy for cervical carcinoma: factors determining response and implications for clinical trial design. *J Clin Oncol* 1998;16:1879–1884.
392. Moore DH, Blessing JA, McQuellon RP, et al. Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study. *J Clin Oncol* 2004;22:3113–3119.
393. Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol* 2005;23:4626–4633.
394. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol* 2009;27:4649–4655.
395. Kitagawa R, Katsumata N, Ando M, et al. A multi-institutional phase II trial of paclitaxel and carboplatin in the treatment of advanced or recurrent cervical cancer. *Gynecol Oncol* 2012;125:307–311.
396. Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical cancer. *N Engl J Med* 2014;370:734–743.
397. Monk BJ, Mas Lopez L, Zarba JJ, et al. Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer. *J Clin Oncol* 2010;28:3562–3569.

398. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. *Gynecol Oncol* 2011;122:495–500.
399. Mahé MA, Gérard JP, Dubois JB, et al. Intraoperative radiation therapy in recurrent carcinoma of the uterine cervix: report of the French Intraoperative Group on 70 patients. *Int J Radiat Oncol Biol Phys* 1996;34:21–26.
400. Ijaz T, Eifel PJ, Burke T, et al. Radiation therapy of pelvic recurrence after radical hysterectomy for cervical carcinoma. *Gynecol Oncol* 1998;70:241–246.
401. Wang CJ, Lai CH, Huang HJ, et al. Recurrent cervical carcinoma after primary radical surgery. *Am J Obstet Gynecol* 1999;181:518–524.
402. Thomas GM, Dembo AJ, Black B, et al. Concurrent radiation and chemotherapy for carcinoma of the cervix recurrent after radical surgery. *Gynecol Oncol* 1987;27:254–263.
403. Coleman RL, Keeney ED, Freedman RS, et al. Radical hysterectomy for recurrent carcinoma of the uterine cervix after radiotherapy. *Gynecol Oncol* 1994;55:29–35.
404. Manco A, Landoni F, Cormio G, et al. Radical hysterectomy for recurrent or persistent cervical cancer following radiation therapy. *Int J Gynecol Cancer* 1999;9:295–301.
405. Matthews CM, Morris M, Burke TW, et al. Pelvic exenteration in the elderly patient. *Obstet Gynecol* 1992;79:773–777.
406. Berek JS, Howe C, Lagasse LD, et al. Pelvic exenteration for recurrent gynecologic malignancy: survival and morbidity analysis of the 45-year experience at UCLA. *Gynecol Oncol* 2005;99:153–159.
407. Orr JW Jr, Shingleton HM, Hatch KD, et al. Gastrointestinal complications associated with pelvic exenteration. *Am J Obstet Gynecol* 1983;145:325–332.
408. Roberts WS, Cavanaugh D, Bryson SC, et al. Major morbidity after pelvic exenteration: a seven-year experience. *Obstet Gynecol* 1987;69:617–621.
409. Penalver MA, Barreau G, Sevin BU, et al. Surgery for the treatment of locally recurrent disease. *J Natl Cancer Inst Monogr* 1996;21:117–122.
410. Hawighorst-Knapstein S, Schonefuss G, Hoffmann SO, et al. Pelvic exenteration: effects of surgery on quality of life and body image—a prospective longitudinal study. *Gynecol Oncol* 1997;66:495–500.
411. Ratliff CR, Gershenson DM, Morris M, et al. Sexual adjustment of patients undergoing gracilis myocutaneous flap vaginal reconstruction in conjunction with pelvic exenteration. *Cancer* 1996;78:2229–2235.
412. Hockel M, Baubmann E, Mitze M, et al. Are pelvic side-wall recurrences of cervical cancer biologically different from central relapses? *Cancer* 1994;74:648–655.
413. Roman LD, Morris M, Mitchell MF, et al. Prognostic factors for patients undergoing simple hysterectomy in the presence of invasive cancer of the cervix. *Gynecol Oncol* 1993;50:179–184.
414. Hopkins MP, Peters WA 3rd, Anderson W, et al. Invasive cervical cancer treated initially by standard hysterectomy. *Gynecol Oncol* 1990;36:7–12.
415. Barillot I, Horiot JC, Cuisenier J, et al. Carcinoma of the cervical stump: a review of 213 cases. *Eur J Cancer* 1993;29A:1231–1236.
416. Miller BE, Copeland LJ, Hamberger AD, et al. Carcinoma of the cervical stump. *Gynecol Oncol* 1984;18:100–108.
417. Hacker NF, Berek JS, Lagasse LD, et al. Carcinoma of the cervix associated with pregnancy. *Obstet Gynecol* 1982;59:735–746.
418. Shingleton HM, Orr JW. *Cancer of the Cervix*. Philadelphia, PA: J. B. Lippincott Co.; 1995.
419. Tseng CJ, Hong SG, Soong YK, et al. Conservative conization for microinvasive carcinoma of the cervix. *Am J Obstet Gynecol* 1997;176:1009–1010.
420. Duggan B, Muderspach LI, Roman L, et al. Cervical cancer in pregnancy: reporting on planned delay in therapy. *Obstet Gynecol* 1993;82:598–602.
421. Sood AK, Sorosky JL, Mayr N, et al. Radiotherapeutic management of cervical carcinoma that complicates pregnancy. *Cancer* 1997;80:1073–1078.
422. Van den Broek NR, Lopes AD, Ansink A, et al. “Microinvasive” adenocarcinoma of the cervix implanting in an episiotomy scar. *Gynecol Oncol* 1995;59:297–299.